7369-27-9

Basic information

• Product Name: o-xylene-3,alpha,alpha'-triol
• Synonyms: o-xylene-3,alpha,alpha'-triol;3-Hydroxy-1,2-benzenedimethanol;Einecs 230-921-5
• CAS NO: 7369-27-9
• Molecular Formula: C₈H₁₀O₃
• Molecular Weight: 154.1632
• EINECS: 230-921-5
• Mol File: 7369-27-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 369.3±32.0 °C(Predicted)
• Appearance: /
• Density: 1.334±0.06 g/cm3(Predicted)
• PKA: 9.71±0.10(Predicted)
• CAS DataBase Reference: o-xylene-3,alpha,alpha'-triol(CAS DataBase Reference)
• NIST Chemistry Reference: o-xylene-3,alpha,alpha'-triol(7369-27-9)
• EPA Substance Registry System: o-xylene-3,alpha,alpha'-triol(7369-27-9)

Safety Data

• Hazardous Substances Data: 7369-27-9(Hazardous Substances Data)

Upstream product

• 50-00-0 formaldehyd 
• 37418-88-5 3-hydroxyphthalic anhydride 
• 112429-68-2 2,3-bis(acetoxymethyl)phenyl acetate 

Downstream Products

• 112429-70-6 (2,2-dimethyl-4H-benzo[d][1,3]dioxin-5-yl)methanol 
• 88557-39-5 Acetic acid (1R,2S)-2-acetoxy-1-[(E)-2-(3-hydroxy-2-hydroxymethyl-phenyl)-vinyl]-heptyl ester 
• 88557-40-8 dechloromonilidiol diacetate 
• 85414-35-3 dechloromonilidiol 

Relevant articles and documents

Oxidative dearomatization and unusual intramolecular Diels-Alder reaction of cyclohexa-2,4-dienone: Synthesis and photoreaction of oxa-tricyclo[5.2.2.01,5]undec-10-ene-8-ones

Abstract An efficient synthesis of annulated bicyclo[2.2.2]octane having β,γ-enone chromophoric system and triplet sensitized 1,2-acyl shift rearrangement leading to the formation of angular oxa-triquinane is described. Oxidative dearomatization, intramolecular Diels-Alder reaction of 6,6-spiroepoxycyclohexa-2,4-dienone and oxa-di-π-methane reaction are the key features of our approach.

Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators

This invention relates to compounds which are generally IP receptor modulators, particularly IP receptor agonists, and which are represented by Formula I: wherein R1, R2, R3, R4, R5, A, and B are as defined in the specification, and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.